A number of other analysts have also recently weighed in on AZN. Analysts at Jefferies Group (NYSE: JEF) upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note to investors on Monday. Separately, analysts at Barclays Capital (NYSE: BCS) upgraded shares of AstraZeneca from an “underweight” rating to an “equal weight” rating in a research note to investors on Monday, April 23rd. Finally, analysts at Zacks reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Friday, March 30th. They now have a $47.00 price target on the stock.
AstraZeneca traded up 1.14% on Monday, hitting $44.40. AstraZeneca has a 52-week low of $40.89 and a 52-week high of $52.54. The company has a market cap of $56.566 billion and a price-to-earnings ratio of 6.73.
The company last announced its quarterly results on Thursday, April 26th. It reported $1.81 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $1.73 EPS by $0.08. The company’s quarterly revenue was down 11.4% on a year-over-year basis. Analysts expect that AstraZeneca will post $1.48 EPS next quarter.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines for six areas of healthcare.